Significant Accounting Policies Significant Accounting Policies [Text Block] Investments Investment, Policy [Policy Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] Personnel related research and development expenses Personnel Related Research And Development Expense Personnel Related Research And Development Expense Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Liability Related to the Revenue Participation Right Debt, Policy [Policy Text Block] Tabular List, Table Tabular List [Table Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule Of Cost Sharing Payments And Reimbursements Schedule Of Cost Sharing Payments And Reimbursements [Table Text Block] Schedule Of Cost Sharing Payments And Reimbursements Accounts payable Increase (Decrease) in Accounts Payable Other comprehensive income (loss): Other Comprehensive Income (Loss), Tax [Abstract] Unrealized Holding Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Shares of pre-funded warrants (in shares) Class of Warrant or Right, Outstanding Net loss per share, basic (usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Commercial paper Commercial Paper [Member] Alexander Schuth, M.D. [Member] Alexander Schuth, M.D. Initial investment proceeds multiple, maximum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Maximum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Maximum Proceeds from sale of revenue participation right Proceeds From Sale Of Revenue Participation Right Liability Related to the Revenue Participation Right Agreement Schedule of Reconciliation of Segment Loss Before Income Taxes and Total Consolidated Loss Before Income Taxes Schedule of Segment Reporting Information, by Segment [Table Text Block] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Schedule of Available for Sale Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Stock–based compensation expense Share-Based Payment Arrangement, Noncash Expense Collaborative agreement, aggregate consideration amount Collaborative Agreement, Aggregate Consideration Amount Collaborative Agreement, Aggregate Consideration Amount Transaction costs Royalty Funding Arrangement, Transaction Costs Royalty Funding Arrangement, Transaction Costs Stock Options Options Issued and Outstanding and ESPP Shares Issuable and Outstanding Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Other general and administrative expenses Other General and Administrative Expense Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Liability Related to the Revenue Participation Right Royalty Funding Arrangement [Text Block] Royalty Funding Arrangement Insider Trading Policies and Procedures [Line Items] Total Share-Based Payment Arrangement, Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Goodwill and Intangible Assets Disclosure [Abstract] Issuance of common stock, net of issuance cost (in shares) Stock Issued During Period, Shares, New Issues Current assets: Assets, Current [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited [Member] Takeda pharmaceutical company limited. Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration of Credit Risk and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Collaborative Arrangement, PTV:PGRN Collaborative Arrangement, PTV:PGRN [Member] Collaborative Arrangement, PTV:PGRN Cover [Abstract] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure General and administrative General and Administrative Expense [Member] Equity Method Investment [Table] Equity Method Investment [Table] Accounting Policies [Abstract] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance lease cost: Finance Lease, Cost [Abstract] Finance Lease, Cost Schedule of Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Right-of-use asset amortization for finance lease Amortization of ROU assets Finance Lease, Right-of-Use Asset, Amortization Entity Shell Company Entity Shell Company Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Contingent payments upon achievement of milestones Contingent Payments Upon Achievement Of Milestones Contingent Payments Upon Achievement Of Milestones Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expired (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Number of new contracts Collaborative Arrangement, Number Of New Contracts Collaborative Arrangement, Number Of New Contracts Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Operating lease liability, current Operating Lease, Liability, Current Interest Finance Lease, Interest Expense Document Fiscal Period Focus Document Fiscal Period Focus Issuances under equity incentive plans (in shares) Stock Issued During Period, Shares, Equity Incentive Plan Stock Issued During Period, Shares, Equity Incentive Plan Peripheral Program License Peripheral Product [Member] Peripheral Product Accounts Receivable Receivable [Policy Text Block] Accrued clinical and other research & development costs Accrued Clinical And Other Accrued Research And Development Costs Accrued Clinical And Other Accrued Research And Development Costs Award Timing Method Award Timing Method [Text Block] Expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Date Fair Value Award Type [Axis] Award Type [Axis] Total assets Assets Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Investing activities Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract] Trading Symbol Trading Symbol Vested and released (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Deferred research and development funding liability Increase (Decrease) In Deferred Liability, Capitalized Research and Development Costs Increase (Decrease) In Deferred Liability, Capitalized Research and Development Costs Entity Address, City or Town Entity Address, City or Town Additional payment Royalty Funding Arrangement, Additional Payment Royalty Funding Arrangement, Additional Payment Intangible Assets Intangible Assets Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Personnel related general and administrative expenses Personnel Related General And Administrative Expense Personnel Related General And Administrative Expense Assets: Assets, Fair Value Disclosure [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Liability related to the revenue participation right agreement Royalty Funding Arrangement Liability, Noncurrent Royalty Funding Arrangement Liability, Noncurrent PEO PEO [Member] Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Purchases of marketable securities Payments to Acquire Marketable Securities Sale of Stock [Domain] Sale of Stock [Domain] Convertible preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Intangible asset, net Intangible Assets, Net (Excluding Goodwill) Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Net cost sharing payments (reimbursements) Research And Development Expense, Offset From Cost Reimbursement Research And Development Expense, Offset From Cost Reimbursement Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Options, exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number Collaboration And Development Funding Agreement Collaboration And Development Funding Agreement [Member] Collaboration And Development Funding Agreement Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other accrued costs and current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Royalty Pharma Royalty Pharma [Member] Royalty Pharma Milestone Triggered Milestone Triggered [Member] Milestone Triggered Pre-funded warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] General and administration Total general and administrative expenses General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Convertible preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Schedule of Assumptions Used for Estimating the Fair Value of Stock Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Total lease costs Lease, Cost Initial investment proceeds multiple, minimum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Minimum Royalty Funding Arrangement, Initial Investment Proceeds Multiple, Minimum Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Lease Costs and Supplemental Information for Lease Amounts Recognized Lease, Cost [Table Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Options, vested and expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Money market funds Money Market Funds [Member] Net accretion of discounts on marketable securities Investment Income, Amortization of Discount Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Equity Components [Axis] Equity Components [Axis] Deferred research and development funding liability, current Deferred Research And Development Funding Liability, Current Deferred Research And Development Funding Liability, Current Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product Product [Member] Number of reportable segments Number of Reportable Segments Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Long-term marketable securities: Long Term Marketable Securities [Member] Long term marketable securities. Interest and other income, net Segment interest and other income, net Interest and Other Income Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Address, State or Province Entity Address, State or Province Payments for finance lease right-of-use asset Finance Lease, Principal Payments Marketable Securities Marketable Securities, Policy [Policy Text Block] Total current liabilities Liabilities, Current Over-Allotment Option Over-Allotment Option [Member] Individual: Individual [Axis] Research and development Research and Development Expense [Member] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Project [Domain] Project [Domain] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Operating lease cost Operating Lease, Cost Operating activities Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Authorized funding Royalty Funding Arrangement, Authorized Funding Royalty Funding Arrangement, Authorized Funding External research and development expense External Research And Development Expense External Research And Development Expense Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity [Abstract] Purchase commitments Purchase Obligation Segment Information Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. government treasuries US Treasury Securities [Member] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Other Commitments [Line Items] Other Commitments [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Long-term marketable securities Marketable Securities, Noncurrent Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] LRRK2 Product LRRK2 Product [Member] LRRK2 Product Leases Lessee, Leases [Policy Text Block] Accrued manufacturing costs Accrued Manufacturing Costs Accrued Manufacturing Costs Franchisor Disclosure [Line Items] Franchisor Disclosure [Line Items] Depreciation and amortization Depreciation, Depletion and Amortization Other non-current assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key PEO Name PEO Name Net proceeds Sale of Stock, Consideration Received on Transaction Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Takeda Collaboration Agreement Takeda Collaboration Agreement [Member] Takeda Collaboration Agreement Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Segments [Axis] Segments [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Reduction to research and development expense Reduction To Research And Development Expense Reduction To Research And Development Expense Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Stock-Based Awards Share-Based Payment Arrangement [Text Block] Assets Assets [Abstract] Biogen Biogen [Member] Biogen Underlying Security Market Price Change Underlying Security Market Price Change, Percent Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Debt Instrument [Axis] Debt Instrument [Axis] Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements Fair Value Disclosures [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Research and development Total research and development expenses Research and Development Expense Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accruals and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Operating lease liability, less current portion Operating Lease, Liability, Noncurrent Deferred research and development funding liability, current Deferred Liability, Capitalized Research And Development Costs, Current Deferred Liability, Capitalized Research And Development Costs, Current Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Fair Value as of Grant Date Award Grant Date Fair Value Receivable Accounts Receivable, after Allowance for Credit Loss Milestone payments upon achievement of certain clinical, regulatory and sales milestone events Aggregate Clinical Regulatory And Sales Milestone Payment Aggregate Clinical Regulatory And Sales Milestone Payment Entity Registrant Name Entity Registrant Name Collaborative Arrangement Collaborative Arrangement [Member] Franchisor, Ownership [Table] Franchisor, Ownership [Table] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Document Quarterly Report Document Quarterly Report Common stock issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Total Assets, Fair Value Disclosure Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Number of operating segments Number of Operating Segments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Milestone Payment Milestone Payment [Member] Milestone Payment Non-PEO NEO Non-PEO NEO [Member] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Sale of Stock [Axis] Sale of Stock [Axis] Unrealized Holding Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name Equity Award [Domain] Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Other non-cash items Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Collaborative Arrangement, ATV:TREM2 Collaborative Arrangement, ATV:TREM2 [Member] Collaborative Arrangement, ATV:TREM2 Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Equity securities without readily determinable fair value, impairment loss Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Financial Instruments [Domain] Financial Instruments [Domain] Segments [Domain] Segments [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Non-cash adjustment to operating lease expense Increase (Decrease) In Non-Cash Operating Lease Expense Increase (Decrease) In Non-Cash Operating Lease Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Biogen Collaborative Arrangement Biogen Collaborative Arrangement [Member] Biogen Collaborative Arrangement Number of securities called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Regulatory Regulatory [Member] Regulatory Company Selected Measure Name Company Selected Measure Name Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Accounts payable Accounts Payable, Current Operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Text Block [Abstract] Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted average number of shares outstanding, diluted (in shares) Weighted average number of shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and contingencies (Note 9) Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Convertible preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Document Transition Report Document Transition Report Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 Preferred Stock, Value, Outstanding Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Project [Axis] Project [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Additional paid-in capital Additional Paid in Capital Product and Service [Axis] Product and Service [Axis] Proceeds from underwriter exercising option to purchase common stock, net of issuance costs Proceeds from Issuance of Common Stock Variable lease cost Variable Lease, Cost Total collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Supply of Commercial Product Supply of Commercial Product [Member] Supply of Commercial Product Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Options, vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Name Forgone Recovery, Individual Name Total current assets Assets, Current Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Short-term marketable securities: Short Term Marketable Securities [Member] Short term marketable securities. Proceeds from exercise of awards under equity incentive plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Common stock shares outstanding (in shares) Weighted Average Number of Shares Issued, Basic Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group Name [Axis] Disposal Group Name [Axis] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Short-term marketable securities Marketable Securities, Current Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Effective maturity (less than) Debt Securities, Available-for-Sale, Term Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] Net unrealized gain (loss) on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Level 1 Fair Value, Inputs, Level 1 [Member] Net loss per share, diluted (usd per share) Earnings Per Share, Diluted Commercial Commercial [Member] Commercial Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Therapeutics Segment Therapeutics Segment [Member] Therapeutics Segment Title of 12(b) Security Title of 12(b) Security Royalty rate Royalty Funding Arrangement, Royalty Rate Royalty Funding Arrangement, Royalty Rate Off-balance sheet concentrations of credit risk Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount Number of common stock sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Short-term marketable securities: Debt Securities, Available-for-Sale, Current Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Asset Acquisition, Contingent Consideration, Type [Domain] Asset Acquisition, Contingent Consideration, Type [Domain] Asset Acquisition, Contingent Consideration, Type [Domain] Fair value of investment Equity Securities, FV-NI, Noncurrent Exercised (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accrued compensation Employee-related Liabilities, Current Other research and development expenses, including small molecule programs Other Research and Development Expense Common Stock Equity [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Expiration Date Trading Arrangement Expiration Date Organization and Description of Business Organization and Description of Business, Policy [Policy Text Block] Organization and description of business, policy. Other accrued costs and current liabilities Other Accrued Liabilities, Current Property and equipment, net Property, Plant and Equipment, Net Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Convertible preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date Public Offering Public Offering [Member] Public Offering Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-Marketable Equity Investment Investment in Debt and Equity Instruments and Cash and Cash Equivalent [Text Block] Series A Preferred Stock Series A Preferred Stock [Member] Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Financing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Loss from operations Operating Income (Loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Issuances under equity incentive plans Stock Issued During Period, Value, Equity Incentive Plan Stock Issued During Period, Value, Equity Incentive Plan Finance lease liability, current Finance Lease, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Annual interest rate Royalty Funding Arrangement, Interest Rate, Effective Percentage Royalty Funding Arrangement, Interest Rate, Effective Percentage Proceeds recieved Proceeds from Issuance of Long-Term Debt Current Fiscal Year End Date Current Fiscal Year End Date Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Weighted-Average Fair Value at Date of Grant per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Table] Statement [Table] Payment due on intangible asset acquired Noncash or Part Noncash Acquisition, Intangible Assets Acquired Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Research and Development Funding Collaboration Agreement Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Contract liability Contract with Customer, Liability Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Finance lease liability, less current portion Finance Lease, Liability, Noncurrent Potentially dilutive securities not include in the diluted per share calculations (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Loss before income taxes Income (Loss) Attributable to Parent, before Tax Other Commitments [Table] Other Commitments [Table] Termination Date Trading Arrangement Termination Date Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-term marketable securities: Debt Securities, Available-for-Sale, Noncurrent Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Weighted average number of shares outstanding, basic (in shares) Weighted average number of shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Restricted cash Restricted Cash and Cash Equivalent, Noncurrent Options, exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Asset Acquisition, Contingent Consideration, Type [Axis] Asset Acquisition, Contingent Consideration, Type [Axis] Asset Acquisition, Contingent Consideration, Type Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Beginning balance (usd per share) Ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Sanofi Sanofi [Member] Sanofi [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Royalty Agreement Royalty Agreement [Member] Royalty Agreement Use of Estimates Use of Estimates, Policy [Policy Text Block] Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma [Member] Collaborative Arrangement With F-Star And Acquisition Of F-Star Gamma Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of RSU shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Total liabilities Liabilities Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 158,656,318 shares and 156,182,177 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Common Stock, Value, Outstanding Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Operating expenses: Expenses Operating Expenses [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Collaborative Arrangement, PTV:PGRN and ATV:TREM2 Collaborative Arrangement, PTV:PGRN And ATV:TREM2 [Member] Collaborative Arrangement, PTV:PGRN And ATV:TREM2 Tenvie Therapeutics, Inc Tenvie Therapeutics, Inc [Member] Tenvie Therapeutics, Inc Issuance of common stock, net of issuance cost Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Option Fee Payment Option Fee Payment [Member] Option Fee Payment Counterparty Name [Axis] Counterparty Name [Axis] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Common Stock Common Stock [Member] Vested and released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Aggregate Fair Value Debt Securities, Available-for-Sale Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Corporate debt securities Corporate Debt Securities [Member] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation